arrow
N

Nicky J. Welton

Bristol Medical School
H指数:80
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative serious infection and sepsis risks with advanced therapies in IMIDs: A Bayesian network meta-analysis

比较高级疗法在免疫介导的炎症性疾病中严重感染和脓毒症风险的贝叶斯网络Meta分析

2026-09-230
OA
Efficacy, safety, and quality-of-life improvement of chemotherapy regimens for treatment of unresectable pancreatic cancer: a systematic review and network meta-analysis of phase III randomised controlled trials

不可切除胰腺癌化疗方案的有效性、安全性和生活质量改善:一项基于III期随机对照试验的系统评价和网络Meta分析

Heliyon
IF3.6
2026-08-010
OAAI
Spectrum of Models for Assessing the Cost Effectiveness of Total Knee Replacement Implants: A Comparison of Discrete-Time Cohort Markov and Continuous-Time Individual-Level Multistate Models

模型评估全膝关节置换植入物成本效益的谱系:离散时间队列马尔可夫模型与连续时间个体级多状态模型的比较

2026-01-040
PRE
Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease

采用马尔可夫模型和真实世界证据,识别心血管疾病二级预防中成本效益最高的胆固醇治疗升级阈值。

2025-05-240
OA
Effect modification and non-collapsibility together may lead to conflicting treatment decisions: A review of marginal and conditional estimands and recommendations for decision-making

效应修饰和非可 collapsibility(效应合并性)共同可能导致治疗决策的冲突:对边缘和条件估计量的综述及决策建议

2025-03-101
PRE
Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model

缺血性卒中或短暂性脑缺血发作后氯吡格雷抵抗基因型检测的临床和成本效益: 系统评价和经济模型

2024-09-011
OA